Flowers organized the Inaugural WVU Men’s Alumni Basketball Game, which was held Aug. 1 at Morgantown High School. He donated $6,100 to the Norma Mae Huggins Cancer Research Endowment Fund, which was established by Coach Bob Huggins in memory of his mother, who died from colon cancer.
“It feels good to give back to the community and help Coach Huggins’ cause,” Flowers said. “The coach has helped me out so much over the years through basketball and through life, and I wanted to find a way to pay him back.”
The Huggins Fund supports clinical trials at the WVU Cancer Center.
“This was very thoughtful of John and his basketball colleagues,” John Naim, Ph.D., director of the WVU Cancer Center’s Clinical Trials Research Unit, said. “This gift will be used to support the infrastructure to run clinical trials that are critically important in the development of new cancer treatments.”
Photo caption: Former WVU Men’s Basketball player John Flowers presents John Naim, Ph.D., director of the WVU Cancer Center's Clinical Trials Research Unit, with a $6,100 check from the Inaugural WVU Men’s Alumni Basketball Game.
The WVU Cancer Institute is the first institution in the United States to offer intraoperative radiation therapy (IORT) to treat glioblastoma.
Several events at this year’s West Virginia Writers’ Workshop, July 20-23 at WVU, are focused on the role of writing and storytelling in health. Presenters include narrative medicine faculty from several campuses across the U.S., along with the leaders of an expressive writing program for patients at the WVU Cancer Institute. Health sciences faculty, staff and students are invited to participate in some or all of the Workshop.
WVU cancer researcher participates in study that shows promising treatments for certain patients with advanced colorectal cancer
A group of cancer researchers, including Richard Goldberg, M.D., director of the WVU Cancer Institute, released a study today in the Journal of the American Medical Association comparing the results of combinations of chemotherapy delivered with targeted therapy drugs in the treatment of people with advanced colorectal cancer who had not received prior drug treatment for their advanced disease.